DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price gapped down before the market opened on Monday . The stock had previously closed at $14.70, but opened at $14.22. DBV Technologies shares last traded at $14.33, with a volume of 25,982 shares traded.

Wall Street Analysts Forecast Growth

DBVT has been the topic of several recent analyst reports. Guggenheim reiterated a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a report on Monday, May 4th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citizens Jmp upped their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Trading Down 2.4%

The stock has a market capitalization of $841.97 million, a PE ratio of -4.05 and a beta of -0.95. The firm’s fifty day moving average is $16.91 and its 200-day moving average is $19.41.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. As a group, equities analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Large investors have recently made changes to their positions in the stock. UBS Group AG raised its holdings in shares of DBV Technologies by 165,347.3% in the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after buying an additional 244,714 shares during the period. Diversify Wealth Management LLC purchased a new position in DBV Technologies during the 1st quarter valued at about $1,293,000. Dorsey Wright & Associates purchased a new position in DBV Technologies during the 1st quarter valued at about $2,142,000. Polymer Capital Management HK LTD purchased a new position in DBV Technologies during the 4th quarter valued at about $1,236,000. Finally, AdvisorShares Investments LLC acquired a new position in DBV Technologies in the 1st quarter valued at about $1,052,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.